{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:40:56Z","timestamp":1789594856234,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 2018\/362"],"award-info":[{"award-number":["CAN 2018\/362"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jbc.2022.102238","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T20:03:15Z","timestamp":1657137795000},"page":"102238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib"],"prefix":"10.1016","volume":"298","author":[{"given":"Baswanth","family":"Oruganti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lindahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahid","family":"Amiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9038-6493","authenticated-orcid":false,"given":"Rezwan","family":"Rahimullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":false,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2022.102238_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/TCRM.S1527","article-title":"Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec\u00ae, GleevecTM)","volume":"4","author":"Henkes","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jbc.2022.102238_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2022.102238_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, A selective inhibitor of native and mutant bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2022.102238_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jbc.2022.102238_bib5","first-page":"375","article-title":"SKI-606, a 4-Anilino-3-quinolinecarbonitrile dual inhibitor of src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102238_bib6","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2022.102238_bib7","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbc.2022.102238_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029828","article-title":"Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain","volume":"7","author":"Levinson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102238_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.jbc.2022.102238_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer cell"},{"key":"10.1016\/j.jbc.2022.102238_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukaemia or philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jbc.2022.102238_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2022.102238_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","article-title":"The catalytic activity of Abl1 single and compound mutations: implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia","volume":"1863","author":"Georgoulia","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.jbc.2022.102238_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2022.102238_bib15","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jbc.2022.102238_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2022.102238_bib18","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbc.2022.102238_bib19","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jbc.2022.102238_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12885-020-06782-9","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"Lindstr\u00f6m","year":"2020","journal-title":"BMC cancer"},{"key":"10.1016\/j.jbc.2022.102238_bib21","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.26231","article-title":"Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib","volume":"96","author":"Hall","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbc.2022.102238_bib22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/acscentsci.7b00211","article-title":"Allosteric communication networks in proteins revealed through pocket crosstalk analysis","volume":"3","author":"La Sala","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.jbc.2022.102238_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10930-019-09820-z","article-title":"A\u00a0synergistic combination against chronic myeloid leukemia: an intramolecular mechanism of communication in BCR\u2013ABL1 resistance","volume":"38","author":"El Rashedy","year":"2019","journal-title":"Protein J."},{"key":"10.1016\/j.jbc.2022.102238_bib24","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","article-title":"Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib","volume":"18","author":"Manley","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.bmcl.2011.02.029","article-title":"Hybrid compounds as new bcr\/abl inhibitors","volume":"21","author":"Wang","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bmcl.2012.11.111","article-title":"Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors","volume":"23","author":"Duveau","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jbc.2022.102238_bib27","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.bmcl.2015.07.006","article-title":"Hybrid pyrimidine alkynyls inhibit the clinically resistance related bcr-AblT315I mutant","volume":"25","author":"Lu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jbc.2022.102238_bib28","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-Chloro-6-Methyl-Phenyl)-2-(6-(4-(2-Hydroxyethyl)-Piperazin-1-yl)-2-Methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual src\/abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","article-title":"Crystal structure of the T315I mutant of Abl kinase","volume":"70","author":"Zhou","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jbc.2022.102238_bib30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region\u2013abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib31","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1021\/acs.jmedchem.6b00065","article-title":"Rapid discovery and structure\u2013activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase","volume":"59","author":"Fraser","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib32","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/prot.25368","article-title":"The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib","volume":"85","author":"Friedman","year":"2017","journal-title":"Proteins"},{"key":"10.1016\/j.jbc.2022.102238_bib33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/jp511792a","article-title":"Computational study of the \"DFG-Flip\" conformational transition in C-Abl and C-src tyrosine kinases","volume":"119","author":"Meng","year":"2015","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.jbc.2022.102238_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1073\/pnas.0811223106","article-title":"A\u00a0conserved protonation-dependent switch controls drug binding in the Abl kinase","volume":"106","author":"Shan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2022.102238_bib35","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1021\/acs.jctc.1c00505","article-title":"Activation of Abl1 kinase explored using well-tempered metadynamics simulations on an essential dynamics sampled path","volume":"17","author":"Oruganti","year":"2021","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.jbc.2022.102238_bib36","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1021\/ja210751t","article-title":"The different flexibility of C-src and C-Abl kinases regulates the accessibility of a druggable inactive conformation","volume":"134","author":"Lovera","year":"2012","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.jbc.2022.102238_bib37","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1021\/acs.jctc.7b01170","article-title":"Predicting the conformational variability of Abl tyrosine kinase using molecular dynamics simulations and markov state models","volume":"14","author":"Meng","year":"2018","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.jbc.2022.102238_bib38","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1371\/journal.pbio.0040144","article-title":"A\u00a0src-like inactive conformation in the Abl tyrosine kinase domain","volume":"4","author":"Levinson","year":"2006","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jbc.2022.102238_bib39","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1039\/D0CC02164D","article-title":"Is breaking of a hydrogen bond enough to lead to drug resistance?","volume":"56","author":"D\u00e1vila-Rodr\u00edguez","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jbc.2022.102238_bib40","article-title":"A\u00a0new local density functional for main-group thermochemistry, transition metal bonding, thermochemical kinetics, and noncovalent interactions","volume":"125","author":"Zhao","year":"2006","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jbc.2022.102238_bib42","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbc.2022.102238_bib43","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1021\/ja100936w","article-title":"Revealing noncovalent interactions","volume":"132","author":"Johnson","year":"2010","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.jbc.2022.102238_bib44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btaa826","article-title":"Synergy: a python library for calculating, analyzing and visualizing drug combination synergy","volume":"37","author":"Wooten","year":"2021","journal-title":"Bioinform"},{"key":"10.1016\/j.jbc.2022.102238_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","article-title":"GROMACS: a message-passing parallel molecular dynamics implementation","volume":"91","author":"Berendsen","year":"1995","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.jbc.2022.102238_bib46","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib47","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.100.020603","article-title":"Well-tempered metadynamics: a smoothly converging and tunable free-energy method","volume":"100","author":"Barducci","year":"2008","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.jbc.2022.102238_bib48","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.cpc.2009.05.011","article-title":"PLUMED: a portable plugin for free-energy calculations with molecular dynamics","volume":"180","author":"Bonomi","year":"2009","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.jbc.2022.102238_bib49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.cpc.2013.09.018","article-title":"PLUMED 2: new feathers for an old bird","volume":"185","author":"Tribello","year":"2014","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.jbc.2022.102238_bib50","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data","volume":"34","author":"Huang","year":"2013","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib51","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib52","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh ewald: an N\u00b7log(N) method for ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib53","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A\u00a0smooth particle mesh ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib54","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"Lincs: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jcc.540130805","article-title":"Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models","volume":"13","author":"Miyamoto","year":"1992","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib56","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"Bussi","year":"2007","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib57","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib58","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J.\u00a0Appl. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1107\/S0907444902003451","article-title":"The protein data bank","volume":"58","author":"Berman","year":"2002","journal-title":"Acta Crystallogr. Sect. D: Biol. Crystallogr."},{"key":"10.1016\/j.jbc.2022.102238_bib60","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2022.102238_bib61","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib62","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/(SICI)1521-3773(19990115)38:1\/2<236::AID-ANIE236>3.0.CO;2-M","article-title":"Peptide folding: when simulation meets experiment","volume":"38","author":"Daura","year":"1999","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jbc.2022.102238_bib63","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1073\/pnas.202427399","article-title":"Escaping free-energy minima","volume":"99","author":"Laio","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2022.102238_bib64","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/wcms.31","article-title":"Metadynamics","volume":"1","author":"Barducci","year":"2011","journal-title":"Wires Comput. Mol. Sci."},{"key":"10.1016\/j.jbc.2022.102238_bib65","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/ct3002464","article-title":"Metadynamics with adaptive Gaussians","volume":"8","author":"Branduardi","year":"2012","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.jbc.2022.102238_bib66","doi-asserted-by":"crossref","first-page":"090601","DOI":"10.1103\/PhysRevLett.96.090601","article-title":"Equilibrium free energies from nonequilibrium metadynamics","volume":"96","author":"Bussi","year":"2006","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.jbc.2022.102238_bib67","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"Plip: fully automated protein\u2013ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.jbc.2022.102238_bib68","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1039\/b508541a","article-title":"Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy","volume":"7","author":"Weigend","year":"2005","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib69","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1021\/jp810292n","article-title":"Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions","volume":"113","author":"Marenich","year":"2009","journal-title":"J.\u00a0Phys. Chem. B"},{"key":"10.1016\/j.jbc.2022.102238_bib70","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.cpc.2010.04.018","article-title":"NWChem: a comprehensive and scalable open-source solution for large scale molecular simulations","volume":"181","author":"Valiev","year":"2010","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.jbc.2022.102238_bib71","article-title":"Recent developments in the general atomic and molecular electronic structure system","volume":"152","author":"Barca","year":"2020","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.jbc.2022.102238_bib72","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/jcc.540141112","article-title":"General atomic and molecular electronic structure system","volume":"14","author":"Schmidt","year":"1993","journal-title":"J.\u00a0Comp. Chem."},{"key":"10.1016\/j.jbc.2022.102238_bib73","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/ct100641a","article-title":"NCIPLOT: a program for plotting noncovalent interaction regions","volume":"7","author":"Contreras-Garc\u00eda","year":"2011","journal-title":"J.\u00a0Chem. Theor. Comput."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822006809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822006809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:31:27Z","timestamp":1758241887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925822006809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0021925822006809"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2022.102238","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2022.102238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"102238"}}